FUNDING Centre Funding by CINSW $ 5,836, 957 Centre Co-Funding by - PowerPoint PPT Presentation

FUNDING Centre Funding by CINSW $ 5,836, 957 Centre Co-Funding by Usyd $ 1,000, 000 80% research infrastructure and direct research support 20% admin (2.6FTE Administration)

CINSW Goals for Translational Cancer Research Centres: 1. Facilitate the generation of practice improving research and its more rapid adoption for improved patient outcomes. 2. Facilitate evidence into practice research . 3. Facilitate the more efficient and effective incorporation of research in:  Clinical training  Education  Service delivery Within formal governance structure that supports networks and enhanced collaboration 4. Build capacity in research and improve competitive advantage in securing other funds .

SYDNEY VITAL Vision: Establish Sydney Vital as a competitive network of excellence in conducting collaborative translational research to improve patient outcomes. Mission: Encourage and promote innovation and collaboration among preclinical and clinical researchers to support cancer research across the translational research pipeline. Business Goal: Making sure the right patient gets the right treatment at the right time as a result of the translational research.

SYDNEY VITAL OBJECTIVES Self sustainable by 2019. Enhance collaborations. Develop and maintain essential research infrastructure. Build a process to link the right people to do research. Facilitate comprehensive research training and educational programs Identify process disseminate research findings and support the implementation of evidence into practice in an efficient manner. Standardise process to identify right questions that align with health priorities. Leverage funding opportunities and increase competitive advantage Build a supportive governance structure

TRANSLATIONAL RESEARCH IN A NUTSHELL

SYDNEY VITAL TRANSLATIONAL Cancer RESEARCH PLAN T3 T2 T1 POLICY & CLINICAL IMPLEMENTATION CLINICAL BASIC TRANSLATIONAL PRACTICES SCIENCE SERVICES SCIENCE SCIENCE SCIENCE Flagship 1 Flagship 2 Flagship 3 Flagship 4 Pillar 1 Pillar 2 Pillar 5 Pillar 3 Pillar 4

Capacity Building 9 Research Scholars 5 Pillar initiatives # Seed Funding Research Infrastructure SV supports 2.0 FTE Bio-banking Officers Kolling biobank SV supports 0.3 FTE research pathologist. Pathology research platform

SYDNEY VITAL RESEARCH PROGRAMS Program Supervisor/ Awardees Awarded Activity Program Title Period Alignment Leader Amount Investigation of novel insulin-like growth factor (GF)-and sphingosine kinase Flagship 1 (sphK)-targeted-therapies for ER-negative, therapy-resistant breast cancer Pillar 3 Prof Baxter Dr Ochnik $65,000 2014-2015 (T1-T2) Professionalising the Multidisciplinary team Meetings in Neureondocrine Flagship 2 Pillar 1, 2 & 5 Prof Bailey Dr Chan $65,000 2014-2015 Tumours (T1-T2-T3) Development and pilot implementation of an evidence-based clinical pathway Flagship 3 and toolkit for survivorship care in young women with breast cancer at high Pillar 3 & 4 Prof Boyle Dr Dhillon $65,000 2014-2015 risk of stopping endocrine therapy prematurely (T2-T3) Nano Medicine in Oncology: improved preoperative staging and better A/Prof Engel & Prof Flagship 4 Pillar 1, 2, &3 2015-2016 understanding of chemotherapy delivery n (T1-T2-T3) Dale Bailey Seed Funding Alllocated to Flagship 4 to support the Nano Medicine project that is being A/Prof Engel & Prof $80,000 developed Bailey Pillar 1 Defining and achieving state of the art cancer diagnosis and treatment Prof Bailey $15,000 2014-2015 Pillar 2 Determining why and when early stage cancer recurs Dr Howell $15,000 2014-2015 Pillar 3 Understanding and overcoming mechanisms of resistance in tumours Prof Marsh $15,000 2014-2015 Pillar 4 Supportive Care, end-Stage Tumours, and end-of-life management Prof Boyle $15,000 2014-2015 Pillar 5 Hereditary Cancer Syndromes A/Prof Gill $15,000 2014-2015 Noncoding RNAs as tumour suppressors in adrenal cancer: Unlocking the Scholarship Prof Sidhu Dr Glover $15,000 2014-2015 mechanisms to improve patient outcomes. A Role for p14ARF-p53 in Treatment Resistance and Recurrence in Scholarship Dr Nassif Dr Hatoum $15,000 2014-2015 Hormone-dependent Breast Cancer. The bench-to-bedside clinical implementation of real-time targeted Scholarship Prof Keall Dr Colvill $15,000 2014-2015 radiotherapy for prostate cancer Gene expression profiling of high-grade B-cell lymphomas with NanoString nCounter technology. Validation of a novel diagnostic platform and Scholarship Prof Stevenson Dr Gifford $15,000 2014-2015 implementation into clinical use for prognostication and therapeutic decision- making. Chemotherapeutic prodrugs incorporated within recombinant high density Scholarship Prof Smith Dr Bulanadi $15,000 2014-2015 lipoprotein nanoparticles as a modality of targeted delivery. Scholarship Currently being assessed TBA TBA $15,000 2014-2015 Scholarship Currently being assessed TBA TBA $15,000 2014-2015 Scholarship Currently being assessed TBA TBA $15,000 2014-2015 Currently being assessed TBA TBA $15,000 2014-2015 Scholarship Total $485,000 2014-2015

Flagship 1 Investigation of novel insulin-like growth factor (IGF)-and sphingosine kinase (SphK)-targeted therapies for ER-negative, therapy-resistant breast cancer (T1-T2). Flagship Lead Rob Baxter Stephen Clarke, CIs Debbie Marsh, Fran Boyle, Anthony Gill Mark Molloy Proposal Title: Investigation of novel insulin-like growth factor (IGF)- and sphingosine kinase (SphK)-targeted therapies for ER-negative, therapy-resistant breast cancer. R. Fellow Aleksandra Ochnik

Flagship 2 NETwork (multidisciplinary management of Neureondocrine Tumors (T1-T2-T3). Flagship Dale Bailey Lead Alexander Engel Stephen Clarke CIs Anthony Gill Debbie Marsh Project Title: Professionalising the Multidisciplinary team R. Fellow David Chan Meetings in Neureondocrine Tumours (T1-T2-T3)

Flagship 3 Development and pilot implementation of an evidence-based clinical pathway and toolkit for survivorship care in young women with breast cancer at high risk of stopping endocrine therapy prematurely (T2-T3). Flagship Lead Fran Boyle Debbie Marsh CIs Stephen Clarke Mark Molloy Proposal Title : Development and pilot implementation of an Haryana Dhillon R. Fellow evidence-based clinical pathway and toolkit for survivorship care in young women with breast cancer at high risk of stopping endocrine therapy prematurely.

Flagship 4 Nano Medicine in Oncology: improved preoperative staging and better understanding of chemotherapy delivery (T1-T2-T3). Flagship Lead: Alexander Engel CIs Zdenka Kuncic Ewa Goldys Dale Bailey R. Fellow Robert Knox

Pillar 1 Defining and achieving state of the art cancer diagnosis and treatment. Dale Bailey Chief Investor Anubhav Mittal Pillar Leaders Christopher Krisp

Pillar 2 Determining why and when early stage cancer recurs. Chief Investor Viive Howell Helen Wheeler Nham Tran Pillar Leaders Connie Diakos Kelly Charles

Pillar 3 Understanding and overcoming mechanisms of resistance in tumours. Debbie Marsh Chief Investor Pillar Leaders Helen Wheeler Nham Tran Connie Diakos Kelly Charles

Pillar 4 Supportive care, end-stage tumours, and end-of-life management. Chief Investor Fran Boyle, Josephine Clayton Pillar Leaders Melanie Lovell April Wong Fred Farzin

Pillar 5 Hereditary Cancer Syndromes. Chief Investor Anthony Gill Fred Farzin Pillar Leaders Chou Dr Crook Michelle Houang

SYDNEY VITAL LEAVERAGED FUNDS Flagship Funding Title CIs Amount Funders Project A/Prof Gill Nanostring nCounter system $ 250,000 PAM Flagship 1&2 A/Prof Engel A/ProfEngel Neuroendocrine Tumour Preceptorship $ 38,900 NOVARTIS Flagship 2 A/Prof Pavlakis A/Prof Engel New Paradigms in Rectal Cancer $ 16,500 PETNET Solutions Flagship 2 Prof Bailey A/Prof Engel Educational Support Grant $ 16,500 ANSTO Flagship 2 Prof Bailey New Advances Using PET and Radionuclide A/Prof Engel $ 16,500 PETNET Solutions Flagship 2 Therapy Prof Bailey Support salary for Flagship 2 ( FTE 0.4) Dr.Chan $ 65,000 SIRTeX Flagship 2

CINSW Fundings Funding Title CINSW Scheme CIs Amount Funders Status Marsh DJ, Baxter RC, NanosStreamlining specimen preparation for UNDER CINSW Research Equipment Smith RC, researchers from samples stored in $ 83,797 CINSW MEDIA Grants Scheme Howell VM, biobanks,tring nCounter system EMBARGO Benn DE, and Engel A Molloy M, Baxter RC, Boyages J, Boyle F, UNDER MS for cancer drug monitoring and biomarker CINSW Research Equipment Clarke S, CINSW MEDIA $ 468,000 studies Grants Scheme Min G, EMBARGO Packer N, Pavlakis N, Anderson M, and Engel A Prof Sharon Kilbreath, A/Prof Kerry Sherman, Prof Fran Boyle AM, Prof Dale Bailey, Improving quality of life for cancer patietns CINSW Translational Progam Will be $ 3,750,000 CINSW A/Prof Mark Molloy, with Lymphoedema and their carers Grant resubmitted Ass/Prof Hiroo Suami, and Prof Sheila Ridner Dr Blake Dear, Prof Ewa Goldys the further expansion, maintenance and deployment of a tissue bank of paraffin CINSW Research Infrastructure Applied in $ 228,537 CINSW blocks containing cancers to mirror and Grant May 2015 A/Prof Anthony Gill expand frozen tissue tumour bank assets ” . MALDI MS Imaging at Sydney Vital for CINSW Research Infrastructure Applied in Prof Baxter RC xxx CINSW Cancer Biomarker Discovery Grant May 2015